NCT05398224Unknown2 期
Phase II Study of Zanubrutinib in Combination With Rituximab and Methotrexate, Followed by Zanubrutinib Maintenance in Patients With Secondary Central Nervous System Lymphoma (SCNSL)
Peking University1 个研究点 分布在 1 个国家目标入组 45 人开始时间: 2021年2月26日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 45
- 试验地点
- 1
- 主要终点
- progression free survival
研究概览
简要总结
Secondary central nervous system lymphoma (SCNSL) occurred in about 5% of patients with diffuse large B-cell lymphoma (DLBCL). The prognosis of SCNSL is very poor. A number of retrospective studies have shown that the median overall survival (mOS) since the diagnosis of CNSL is only 2.5-3.5 months, and the 2-year OS rate is only 20%. At present, there is no consensus on the treatment of SCNSL, and new therapeutic strategies are urgently needed. Zanubrutinib is a new second-generation BTK inhibitor, which has showed good efficacy and safety in a variety of B-NHL. Zanubrutinib has showed good blood-brain barrier permeability in preclinical studies. This study attempts to evaluate the efficacy and safety of zanubrutinib combined with rituximab and high-dose methotrexate in the treatment of SCNSL in patients with DLBCL.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men and women ≥ 18, and ≤75 years of age
- •Histologically documented systemic diffuse large B-cell lymphoma(DLBCL)
- •Central nervous system (CNS) relapse (meningeal or /and intraparenchymal) with or without systemic lymphoma manifestations
- •All patients need to have received at least one and ≤4 lines of prior therapy systemic lymphoma directed therapy.
- •ECOG performance score 0-3
- •Participants must have adequate bone marrow and organ function shown by:
- •Absolute neutrophil count (ANC) ≥ 1.5 x 109/L, Hemoglobin (Hgb) ≥ 9 g/dL, Platelets ≥ 75 x 109/L(≥ 50 x 109/L if bone marrow involvement)
- •Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times the upper limit of normal, total bilirubin ≤ 2 times the upper limit of normal
- •International Normalized Ratio (INR) ≤ 1.5 and PTT (aPTT) ≤ 1.5 times the upper limit of normal
- •serum creatinine (mg/dL)) ≤ 1.5 times the upper limit of normal ; calculated creatinine clearance(CrCl) ≥ 40ml/min using the Cockcroft-Gault equation
- •Expected survival greater than 3 months
- •Did not receive targeting agents within 10 days or receive chemortherapy, radiotherapy, or monoclonal antibody within 3 weeks
- •Woman of reproductive potential must agree to use highly effective methods of birth control during the period of therapy and for 30 days after the last dose of the study drug. Men who are sexually active must agree to use highly effective contraception during the period of therapy and for 3 months after the last dose
- •Ability of participants or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document
排除标准
- •Newly diagnosed DLBCL with CNS involvement
- •Previous treatment with Bruton's Tyrosine Kinase (BTK) inhibitors
- •Received targeting agents within 10 days or received chemortherapy, radiotherapy, or monoclonal antibody within 3 weeks
- •Patient has significant abnormalities on screening electrocardiogram (EKG) and active and significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, hypertension, valvular disease, pericarditis, or myocardial infarction within 6 months of screening
- •History of severe bleeding diseases
- •Patient is using warfarin or any other Coumadin-derivative anticoagulant or vitamin K antagonists. Patients must be off warfarin-derivative anticoagulants for at least seven days prior to starting the study drug. Low molecular weight heparin is allowed. Patients with congenital bleeding diathesis are excluded
- •Patient is taking a drug known to be a moderate and strong inhibitor or inducers of the P450 isoenzyme CYP3A. Participants must be off P450/CYP3A inhibitors and inducers for at least two weeks prior to starting the study drug
- •Patient is known to have human immunodeficiency virus (HIV) infection
- •Patient is known to have a history of active or chronic infection with hepatitis C virus (HCV) or hepatitis B virus (HBV) as determined by serologic tests
- •Patient is known to have an uncontrolled active systemic infection
- •Patients with serous cavity effustion
- •Patient underwent major systemic surgery ≤ 4 weeks prior to starting the trial treatment or who has not recovered from the side effects of such surgery
- •Women who are pregnant or nursing (lactating)
- •The patient is unwell or unable to participate in all required study evaluations and procedures
研究组 & 干预措施
Experimental arm: Zanubrutinib, high-dose methotrexate (HD-MTX), rituximab
Experimental
Zanubrutinib in combination with rituximab and methotrexate, followed by zanubrutinib maintenance in patients with secondary central nervous system lymphoma (SCNSL)
干预措施: Zanubrutinib, high-dose methotrexate (HD-MTX), rituximab (Drug)
结局指标
主要结局
progression free survival
时间窗: 1-year
Progression-free survival (PFS) is defined as the time from the date of treatment start to the date of the first documented PD or death due to any cause
次要结局
- Complete response (CR)(at the end of 6 cycles of induction therapy)
- Partial response (PR)(at the end of 6 cycles of induction therapy (each cycle is 14 days))
- Overall survival (OS)(1-year)
- Overall response rate (ORR)(at the end of 6 cycles of induction therapy (each cycle is 14 days))
- safety/tolerability by assessing the frequency and severity of adverse events(at the end of 6 cycles of induction therapy (each cycle is 14 days), 1 year and 2 year maintenance therapy)
研究者
Jun Zhu
professor
Peking University Cancer Hospital & Institute
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell LymphomaLymphoma, Mantle-CellLymphoma, Non-HodgkinNCT06427213Henan Cancer Hospital41
已完成
2 期
Zanubrutinib in Participants With Active Proliferative Lupus NephritisLupus NephritisNCT04643470BeiGene177
Unknown
2 期
Phase II Trial of Double Dose of Icotinib in Treating Brain Metastases From Non-small Cell Lung CancerBrain MetastasesNon-small Cell Lung CancerNCT01688713Zhejiang Cancer Hospital20
已完成
2 期
Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)Refractory Mantle Cell LymphomaRelapsed Mantle Cell LymphomaNCT03206970BeiGene86
已完成
2 期
[18F]-Fludarabine PET/MR Imaging for the Assessment of Newly-diagnosed Primary Central Nervous System (CNS) Lymphoma : a Pilot PET-MRI Study2024-512758-62-00Assistance Publique Hopitaux De Paris10